Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Patients With nAMD Successfully Switch From Aflibercept to Ranibizumab

September 10th 2024

By Cameron Santoro

Article

A study found patients with neovascular age-related macular degeneration (nAMD) successfully switched from aflibercept to the biosimilar ranibizumab, despite fluid challenges.

BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars

September 9th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.

Promoting Informed Decision-Making Through Biosimilar Awareness

September 8th 2024

By Cameron Santoro

Video

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, urges stakeholders to provide patient advocacy groups with comprehensive information about specific drugs and drug classes to increase patient understanding of biosimilars and promote informed decision-making.

Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD

September 7th 2024

By Deana Ferreri, PhD

Article

Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD).

The Top 5 Biosimilar Articles for the Week of September 2

September 6th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of September 2, 2024.

Switching From Originator Etanercept to Biosimilar Version Proves Safe, Effective in RA

September 5th 2024

By Skylar Jeremias

Article

Patients with rheumatoid arthritis who switched from the etanercept originator to a biosimilar exhibited similar disease activity and drug persistence compared with those who remained on the originator, indicating that nonmedical switching does not negatively impact treatment outcomes.

The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings

September 4th 2024

By Skylar Jeremias

Article

A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.

Upcoming Biosimilars and the Impact of IRA: Key Takeaways From Jeffrey Casberg

September 3rd 2024

By Cameron Santoro

Article

Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and the evolving role of pharmacy benefit managers in the market.

Biosimilar Uptake Lags in US Despite Potential Cost Savings

September 2nd 2024

By Cameron Santoro

Article

Delayed biosimilar uptake in the US is driven by payer, provider, and patient barriers, but targeted interventions can help boost utilization and savings.

Biosimilars Business Roundup for August 2024—Podcast Edition

September 1st 2024

By Skylar Jeremias

Article

On this episode of Not So Different, the end of the second quarter brings with it expense reports, new biosimilar business deals, and insights into how federal policy impacts biosimilar company pursuits.